Title: Exosurf® (Glaxo Wellcome)
CAS Registry Number: 99732-49-7
CAS Name: (7R)-4-Hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacosan-1-aminium, inner salt, 4-oxide mixture with formaldehyde polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol and 1-hexadecanol
Trademarks: Surfexo (Glaxo Wellcome)
Literature References: C40H80NO8P.C16H34O.(C14H22O.C2H4O.CH2O)x. Protein-free synthetic lung surfactant composed of a 13.5:1.5:1 mixture of colfosceril palmitate, cetyl alcohol and tyloxapol, q.q.v. Prepn: J. A. Clements, US 5110806 (1992 to Univ. of Calif.). Pharmacology: D. J. Durand et al., J. Pediatr. 107, 775 (1985); W. H. Tooley et al., Am. Rev. Respir. Dis. 136, 651 (1987). Clinical trial in neonatal respiratory distress syndrome (RDS): W. Long et al., J. Pediatr. 118, 595 (1991). Symposium on pulmonary mechanics and clinical use in RDS: ibid. 120, Suppl., S1-S50 (1992). Review of pharmacodynamics, clinical efficacy and tolerance: K. L. Dechant, D. Faulds, Drugs 42, 877-894 (1991); of metabolism: R. L. DeAngelis, J. W. Findlay, Clin. Perinatol. 20, 697-710 (1993).
Therap-Cat: Pulmonary surfactant.
Keywords: Pulmonary Surfactant. |